Literature DB >> 35028747

Phenotypic, trophic, and regenerative properties of mesenchymal stem cells from different osseous tissues.

Douhong Zou1, Marina Vigen2, Andrew J Putnam2, Chen Cao1, Susan A Tarlé1, Tyler Guinn1, Darnell Kaigler3,4.   

Abstract

Mesenchymal stem cells (MSCs) have broad-based therapeutic potential in regenerative medicine. However, a major barrier to their clinical utility is that MSCs from different tissues are highly variable in their regenerative properties. In this study, we defined the molecular and phenotypic identities of different MSC populations from different osseous tissue sites of different patients and, additionally, determined their respective regenerative properties. MSCs from 6 patients were isolated from either bone marrow of the iliac crest (BMSCs) or alveolar bone tissue (aBMSCs), and flow cytometry revealed that regardless of the tissue source, MSC immunotypes had the same expression of MSC markers CD73, CD90, and CD105. However, transcriptomic analyses revealed 589 genes differentially expressed (DE) between BMSCs and aBMSCs, including eightfold higher levels of bone morphogenetic protein 4 (BMP-4) in aBMSCs. In striking contrast, gene expression of MSCs derived from the same tissue, but between different patients (i.e., BMSCs to BMSCs, aBMSCs to aBMSCs), showed only 38 DE BMSC genes and 51 DE aBMSC genes. A protein array showed that aBMSC and BMSC produced equivalent levels of angiogenic cytokines; however, when placed in angiogenesis model systems, aBMSCs induced significantly more capillaries in vitro and in vivo. Finally, cell transplantation of MSCS into osseous defects showed that the bone regenerative capacity of aBMSCs was significantly greater than that of BMSCs. This study is the first to link the molecular, phenotypic, and regenerative properties of different MSCs from different patients and provides novel insights toward MSC differences based on the osseous tissue origin.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Angiogenesis; Bone regeneration; Differential gene expression; Mesenchymal stem cells; RNA sequencing

Mesh:

Year:  2022        PMID: 35028747      PMCID: PMC9354673          DOI: 10.1007/s00441-021-03563-z

Source DB:  PubMed          Journal:  Cell Tissue Res        ISSN: 0302-766X            Impact factor:   4.051


  42 in total

1.  Repair of alveolar cleft defect with mesenchymal stem cells and platelet derived growth factors: a preliminary report.

Authors:  Hossein Behnia; Arash Khojasteh; Masoud Soleimani; Azita Tehranchi; Amir Atashi
Journal:  J Craniomaxillofac Surg       Date:  2011-03-21       Impact factor: 2.078

2.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.

Authors:  M Dominici; K Le Blanc; I Mueller; I Slaper-Cortenbach; Fc Marini; Ds Krause; Rj Deans; A Keating; Dj Prockop; Em Horwitz
Journal:  Cytotherapy       Date:  2006       Impact factor: 5.414

3.  Molecular and secretory profiles of human mesenchymal stromal cells and their abilities to maintain primitive hematopoietic progenitors.

Authors:  Wolfgang Wagner; Christoph Roderburg; Frederik Wein; Anke Diehlmann; Maria Frankhauser; Ralf Schubert; Volker Eckstein; Anthony D Ho
Journal:  Stem Cells       Date:  2007-07-05       Impact factor: 6.277

4.  Standardization and safety of alveolar bone-derived stem cell isolation.

Authors:  S Mason; S A Tarle; W Osibin; Y Kinfu; D Kaigler
Journal:  J Dent Res       Date:  2013-10-29       Impact factor: 6.116

5.  A perivascular origin for mesenchymal stem cells in multiple human organs.

Authors:  Mihaela Crisan; Solomon Yap; Louis Casteilla; Chien-Wen Chen; Mirko Corselli; Tea Soon Park; Gabriella Andriolo; Bin Sun; Bo Zheng; Li Zhang; Cyrille Norotte; Pang-Ning Teng; Jeremy Traas; Rebecca Schugar; Bridget M Deasy; Stephen Badylak; Hans-Jörg Buhring; Jean-Paul Giacobino; Lorenza Lazzari; Johnny Huard; Bruno Péault
Journal:  Cell Stem Cell       Date:  2008-09-11       Impact factor: 24.633

6.  Mesenchymal stem cells are injured by complement after their contact with serum.

Authors:  Yan Li; Feng Lin
Journal:  Blood       Date:  2012-09-10       Impact factor: 22.113

7.  Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study.

Authors:  Jun Liang; Huayong Zhang; Bingzhu Hua; Hong Wang; Liwei Lu; Songtao Shi; Yayi Hou; Xiaofeng Zeng; Gary S Gilkeson; Lingyun Sun
Journal:  Ann Rheum Dis       Date:  2010-08       Impact factor: 19.103

8.  Mesenchymal cells stimulate capillary morphogenesis via distinct proteolytic mechanisms.

Authors:  Cyrus M Ghajar; Suraj Kachgal; Ekaterina Kniazeva; Hidetoshi Mori; Sylvain V Costes; Steven C George; Andrew J Putnam
Journal:  Exp Cell Res       Date:  2010-01-11       Impact factor: 3.905

9.  Comparison of the bone regeneration ability between stem cells from human exfoliated deciduous teeth, human dental pulp stem cells and human bone marrow mesenchymal stem cells.

Authors:  Kengo Nakajima; Ryo Kunimatsu; Kazuyo Ando; Toshinori Ando; Yoko Hayashi; Takuya Kihara; Tomoka Hiraki; Yuji Tsuka; Takaharu Abe; Masato Kaku; Hiroki Nikawa; Takashi Takata; Kazuo Tanne; Kotaro Tanimoto
Journal:  Biochem Biophys Res Commun       Date:  2018-03-11       Impact factor: 3.575

10.  Intramyocardial injection of autologous bone marrow-derived ex vivo expanded mesenchymal stem cells in acute myocardial infarction patients is feasible and safe up to 5 years of follow-up.

Authors:  Sander F Rodrigo; Jan van Ramshorst; Georgette E Hoogslag; Helèn Boden; Matthijs A Velders; Suzanne C Cannegieter; Helene Roelofs; Imad Al Younis; Petra Dibbets-Schneider; Willem E Fibbe; Jaap Jan Zwaginga; Jeroen J Bax; Martin J Schalij; Saskia L Beeres; Douwe E Atsma
Journal:  J Cardiovasc Transl Res       Date:  2013-08-28       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.